Advertisement

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival

      Previous studies have suggested that BRCA-related epithelial ovarian cancer (EOC) conveys improved survival compared with that of sporadic EOC, but few studies have evaluated differences between BRCA genotypes. We compared characteristics and outcome by genotype in BRCA-associated EOC. Patients with BRCA-associated EOC who were diagnosed between January 30,1981, and December 30, 2008, were retrospectively identified through institutional review board–approved registry studies. We examined clinical characteristics, including event-free survival (EFS) and overall survival (OS), for BRCA1 versus BRCA2 patients. We identified 197 cases (148 BRCA1 cases; 49 BRCA2 cases); the median follow-up period was 63 months. BRCA2 patients were older (55.4 vs. 51.1 y; P < 0.01) and had fewer poorly differentiated tumors (67% vs. 82%; P < 0.05). No difference in EFS was observed. OS at 5 years was 75% in BRCA2 patients versus 61% in BRCA1 patients; this was not statistically significant. A non-significant trend toward improved OS was observed in BRCA2 patients with advanced-stage disease (hazard ratio = 0.59; 95% confidence interval 0.32–1.08). Age and grade differed significantly between BRCA1 and BRCA2 carriers in our study population. Whereas no overall differences in EFS or OS were observed, there was a trend toward improved OS in BRCA2 carriers with advanced-stage disease. This may reflect important differences between BRCA genotypes and should be validated in larger studies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Risch H.A.
        • McLaughlin J.R.
        • Cole D.E.C.
        • et al.
        Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer.
        Am J Hum Genet. 2001; 68: 700-710
        • Moslehi R.
        • Chu W.
        • Karlan B.
        • et al.
        BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
        Am J Hum Genet. 2000; 66: 1259-1272
        • Robles-Diaz L.
        • Goldfrank D.J.
        • Kauff N.D.
        • et al.
        Hereditary ovarian cancer in Ashkenazi Jews.
        Fam Cancer. 2004; 3: 259-264
        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Pharoah P.D.P.
        • Easton D.F.
        • Stockton D.L.
        • et al.
        Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer.
        Cancer Res. 1999; 59: 868-871
        • Johannsson O.T.
        • Ranstam J.
        • Borg A.
        • et al.
        Survival of BRCA1 Breast and Ovarian Cancer Patients: A Population-Based Study from Southern Sweden.
        J Clin Oncol. 1998; 16: 397-404
        • Rubin S.C.
        • Ivor B.
        • Kian B.
        • et al.
        Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1.
        N Engl J Med. 1996; 335: 1413-1416
        • Aida H.
        • Takakuwa K.
        • Nagata H.
        • et al.
        Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
        Clin Cancer Res. 1998; 4: 235-240
        • Boyd J.
        • Sonoda Y.
        • Federici M.G.
        • et al.
        Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
        JAMA. 2000; 283: 2260-2265
        • Ben David Y.
        • Chetrit A.
        • Hirsh-Yechezkel G.
        • et al.
        Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.
        J Clin Oncol. 2002; 20: 463-466
        • Cass I.
        • Baldwin R.L.
        • Varkey T.
        • et al.
        Improved survival in women with BRCA-associated ovarian carcinoma.
        Cancer. 2003; 97: 2187-2195
        • Majdak E.J.
        • Debniak J.
        • Milczek T.
        • et al.
        Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
        Cancer. 2005; 104: 1004-1012
        • Chetrit A.
        • Hirsh-Yechezkel G.
        • Ben-David Y.
        • et al.
        Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer.
        J Clin Oncol. 2008; 26: 20-25
        • Tan D.S.P.
        • Rothermundt C.
        • Thomas K.
        • et al.
        “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations.
        J Clin Oncol. 2008; 26: 5530-5536
        • Vencken P.M.
        • Kriege M.
        • Hoogwerf D.
        • et al.
        Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
        Ann Oncol. 2011; 22: 1346-1352
        • Foulkes W.D.
        • Metcalfe K.
        • Sun P.
        • et al.
        Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
        Clin Cancer Res. 2004; 10: 2029-2034
        • Ramus S.J.
        • Fishman A.
        • Pharoah P.D.
        • et al.
        Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
        Eur J Surg Oncol. 2001; 27: 278-281
        • Pal T.
        • Permuth-Wey J.
        • Kapoor R.
        • et al.
        Improved survival in BRCA2 carriers with ovarian cancer.
        Fam Cancer. 2007; 6: 113-119
        • Fong P.C.
        • Boss D.S.
        • Yap T.A.
        • et al.
        Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
        N Engl J Med. 2009; 361: 123-134
        • Fong P.C.
        • Yap T.A.
        • Boss D.S.
        • et al.
        Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
        J Clin Oncol. 2010; 28: 2512-2519
        • Tutt A.
        • Robson M.
        • Garber J.E.
        • et al.
        Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 235-244
        • Audeh M.W.
        • Carmichael J.
        • Penson R.T.
        • et al.
        Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 245-251
        • Narod S.A.
        • Foulkes W.D.
        BRCA1 and BRCA2: 1994 and beyond.
        Nat Rev Cancer. 2004; 4: 665-676
        • O’Donovan P.J.
        • Livingston D.M.
        BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.
        Carcinogenesis. 2010; 31: 961-967
        • Quinn J.E.
        • Carser J.E.
        • James C.R.
        • et al.
        BRCA1 and implications for response to chemotherapy in ovarian cancer.
        Gynecol Oncol. 2009; 113: 134-142
        • Sandhu S.K.
        • Wenham R.M.
        • Wilding G.
        • et al.
        First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
        ASCO Meeting Abstracts. 2010; Vol. 28: 3001
        • Gelmon K.A.
        • Hirte H.W.
        • Robidoux A.
        • et al.
        Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.
        ASCO Meeting Abstracts. 2010; Vol. 28: 3002
        • Edwards S.L.
        • Brough R.
        • Lord C.J.
        • et al.
        Resistance to therapy caused by intragenic deletion in BRCA2.
        Nature. 2008; 451: 1111-1115
        • Sakai W.
        • Swisher E.M.
        • Karlan B.Y.
        • et al.
        Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
        Nature. 2008; 451: 1116-1120
        • Swisher E.M.
        • Sakai W.
        • Karlan B.Y.
        • et al.
        Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance.
        Cancer Res. 2008; 68: 2581-2586
        • Sakai W.
        • Swisher E.M.
        • Jacquemont C.
        • et al.
        Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma.
        Cancer Res. 2009; 69: 6381-6386
        • Bunting S.F.
        • Callén E.
        • Wong N.
        • et al.
        53BP1 Inhibits Homologous Recombination in BRCA1-Deficient Cells by Blocking Resection of DNA Breaks.
        Cell. 2010; 141: 243-254
        • Bouwman P.
        • Aly A.
        • Escandell J.M.
        • et al.
        53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
        Nat Struct Mol Biol. 2010; 17: 688-695
        • Turner N.
        • Tutt A.
        • Ashworth A.
        Hallmarks of ‘BRCAness’ in sporadic cancers.
        Nat Rev Cancer. 2004; 4: 814-819
        • Bast Jr., R.C.
        • Mills G.B.
        Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond.
        J Clin Oncol. 2010; 28: 3545-3548
        • Veeck J.
        • Ropero S.
        • Setien F.
        • et al.
        BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
        J Clin Oncol. 2010; 28 (author reply e565–e566): e563-e564
        • Brown L.A.
        • Irving J.
        • Parker R.
        • et al.
        Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
        Gynecol Oncol. 2006; 100: 264-270
        • Konstantinopoulos P.A.
        • Spentzos D.
        • Karlan B.Y.
        • et al.
        Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer.
        J Clin Oncol. 2010; 28: 3555-3561
      1. Bolton K. BRCA2 Mutations Associated with Improved Survival for Ovarian Cancer. Presented at: American Association for Cancer Research 102nd Annual Meeting; April 2–6, 2011; Orlando, FL. [Abstract 2752].

        • Cancer Genome Atlas Research Network
        Integrated genomic analyses of ovarian carcinoma.
        Nature. 2011; 474: 609-615
        • Yang D.
        • Khan S.
        • Sun Y.
        • et al.
        Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
        JAMA. 2011; 306: 1557-1565